Medistim is opening a direct sales office in Sweden

This move is part of the company's ongoing commitment to providing exceptional service to customers as well as fulfilling the company’s global growth strategy. The company is well positioned to continue its growth by further…

Read more

Results for the Third Quarter 2023

Currency neutral sales of own products was down 5.6% for the quarter and up 1.2% YTD September. Operating profit (EBIT) for the quarter ended at MNOK 34 giving a 27.0% EBIT margin (MNOK 34, a…

Read more

Results for the First Quarter 2023

NOK 82.1. The Vascular business segment continues the positive development and grows at 21.5% in NOK, currency neutral 8.8% growth. The Imaging products grow at 9.4% in NOK, currency neutral decline of 3.7%. Currency neutral…

Read more

Annual Report 2022

Further supported by several high-quality symposia at the largest heart surgery conferences, we achieved 44 % growth in the imaging product portfolio in 2022. And while steadily penetrating the Cardiac bypass market, we also build…

Read more

Capital Markets Day

See the recording from Medistim's Capital Markets Day on March 21st where two international thought leaders, Professors John. D. Puskas and Pirkka Vikatmaa shared their insights on the future trends in Cardiac and Vascular Surgery…

Read more

Annual Report 2021

This rebound has continued throughout 2021, and Medistim has experienced strong growth in revenues due to the increase in number of CABG procedures performed. The sales growth was 17.6 % in NOK and operating profit…

Read more

Results for the Third Quarter 2021

Sales revenues for the quarter ended at MNOK 102.1 (MNOK 83.4), an increase of 22.5%. Sales as of September ended at MNOK 309.2 (MNOK 268.9) a 15.0% increase. Sales in the USA increased by 11.9…

Read more